Asthma phenotypes: the intriguing selective intervention with Montelukast
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation and a variable course associated with various underlying mechanisms that can differ between individuals. Patients with asthma can therefore exhibit different phenotypes, a term used to define the observable chara...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142440/ |
| id |
pubmed-5142440 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-51424402016-12-13 Asthma phenotypes: the intriguing selective intervention with Montelukast Marcello, Cottini Carlo, Lombardi Review Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation and a variable course associated with various underlying mechanisms that can differ between individuals. Patients with asthma can therefore exhibit different phenotypes, a term used to define the observable characteristics of an organism resulting from the interaction between its genetic makeup and the environment. The heterogeneity of asthma has received a large amount of attention in the last few years in order to better tailor treatment according to the different clinical and biological phenotypes of the disease. Specific asthma phenotypes may require an approach to treatment sometimes different from that recommended by current guidelines, so a personalized approach to asthma pharmacotherapy is recommended. Growing evidence suggests that leukotrienes play an important role in the pathogenesis of bronchial asthma. The mechanisms of action of leukotriene-receptor antagonists theoretically predict a good response in some asthma “phenotypes”.In this article we have performed an analysis of the recent literature (controlled clinical trials and real-life studies) about a possible selective intervention with Montelukast in specific asthma phenotypes. BioMed Central 2016-08-12 /pmc/articles/PMC5142440/ /pubmed/27965779 http://dx.doi.org/10.1186/s40733-016-0026-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Marcello, Cottini Carlo, Lombardi |
| spellingShingle |
Marcello, Cottini Carlo, Lombardi Asthma phenotypes: the intriguing selective intervention with Montelukast |
| author_facet |
Marcello, Cottini Carlo, Lombardi |
| author_sort |
Marcello, Cottini |
| title |
Asthma phenotypes: the intriguing selective intervention with Montelukast |
| title_short |
Asthma phenotypes: the intriguing selective intervention with Montelukast |
| title_full |
Asthma phenotypes: the intriguing selective intervention with Montelukast |
| title_fullStr |
Asthma phenotypes: the intriguing selective intervention with Montelukast |
| title_full_unstemmed |
Asthma phenotypes: the intriguing selective intervention with Montelukast |
| title_sort |
asthma phenotypes: the intriguing selective intervention with montelukast |
| description |
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation and a variable course associated with various underlying mechanisms that can differ between individuals. Patients with asthma can therefore exhibit different phenotypes, a term used to define the observable characteristics of an organism resulting from the interaction between its genetic makeup and the environment. The heterogeneity of asthma has received a large amount of attention in the last few years in order to better tailor treatment according to the different clinical and biological phenotypes of the disease. Specific asthma phenotypes may require an approach to treatment sometimes different from that recommended by current guidelines, so a personalized approach to asthma pharmacotherapy is recommended. Growing evidence suggests that leukotrienes play an important role in the pathogenesis of bronchial asthma. The mechanisms of action of leukotriene-receptor antagonists theoretically predict a good response in some asthma “phenotypes”.In this article we have performed an analysis of the recent literature (controlled clinical trials and real-life studies) about a possible selective intervention with Montelukast in specific asthma phenotypes. |
| publisher |
BioMed Central |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142440/ |
| _version_ |
1613763257169870848 |